On Aug. 10, 2020, Humanigen announced that the Brazilian regulatory agency, Anvisa, had granted permission to commence a phase III study of lenzilumab in patients with COVID-19 in Brazil.

This study, set to begin recruiting patients in Brazil, followed the same protocol approved by the U.S. FDA in April ﾖ a multicenter, randomized, placebo-controlled, double-blinded clinical trial focused on hospitalized severe and critical adult COVID-19 patients at high risk of disease progression.